Literature DB >> 30044658

Topical drug therapeutics for neuropathic pain.

Terence J Coderre1,2.   

Abstract

INTRODUCTION: Neuropathic pain (NP) is a particularly severe and intractable chronic condition that is not well treated by commonly recommended systemic pharmacological therapies, partly due to dose-limiting side effects or adverse events. The use of topical therapeutics for NP is growing and benefits from the reduced potential for adverse effects, as well as the ability to directly target peripheral pathological processes. AREAS COVERED: The current review defines and describes the limitations of various commonly prescribed systemic pharmacological therapies for NP. It also provides a justification for increased research aimed at developing topical therapeutics for NP, particularly localized and peripheral NP. The review discusses the various classes of topical treatments used for NP, including agents that: block sensory inputs; activate inhibitory systems; provide mechanism-based therapeutics; are used in mucosal tissues; and include combinations that produce multimodal therapeutic effects. EXPERT OPINION: There are arguments that the current topical therapeutics for NP rely too heavily on the use of local anesthetics and capsaicinoids, and more research is certainly needed on topical therapies that are multimodal and/or are targeted at the peripheral sources of pathology. The potential for novel topical therapeutics may be enhanced by further research on topical co-drugs, drug-drug salts, co-crystals and hydrates, and ionic liquids.

Entities:  

Keywords:  NMDA antagonists; NSAIDs; anticonvulsants; antidepressants; capsaicinoids; local anesthetics; multimodal therapy; nitric oxide donors; opioids; Α2-adrenergic agents

Mesh:

Substances:

Year:  2018        PMID: 30044658     DOI: 10.1080/14656566.2018.1501026

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  5 in total

Review 1.  Topical Treatment of Localized Neuropathic Pain in the Elderly.

Authors:  Gisèle Pickering; Camille Lucchini
Journal:  Drugs Aging       Date:  2020-02       Impact factor: 3.923

Review 2.  Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain.

Authors:  Barbara Stella; Francesca Baratta; Carlo Della Pepa; Silvia Arpicco; Daniela Gastaldi; Franco Dosio
Journal:  Drugs       Date:  2021-09-04       Impact factor: 9.546

Review 3.  Modulation of Pathological Pain by Epidermal Growth Factor Receptor.

Authors:  Jazlyn P Borges; Katrina Mekhail; Gregory D Fairn; Costin N Antonescu; Benjamin E Steinberg
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

Review 4.  Expert consensus of the Chinese Association for the Study of Pain on pain treatment with the transdermal patch.

Authors:  Ke Ma; Wei Jiang; Yun-Xia Wang; Lin Wang; Yan Lv; Jin-Feng Liu; Rong-Guo Liu; Hui Liu; Li-Zu Xiao; Dong-Ping Du; Li-Juan Lu; Xiao-Qiu Yang; Ling-Jie Xia; Dong Huang; Zhi-Jian Fu; Bao-Gan Peng; Yan-Qing Liu
Journal:  World J Clin Cases       Date:  2021-03-26       Impact factor: 1.337

5.  Sustained relief of trigeminal neuropathic pain by a blood-brain barrier penetrable PPAR gamma agonist.

Authors:  Morgan Zhang; Min Hu; Marena A Montera; Karin N Westlund
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.